505 related articles for article (PubMed ID: 15120038)
1. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
Kelland LR
Eur J Cancer; 2004 Apr; 40(6):827-36. PubMed ID: 15120038
[TBL] [Abstract][Full Text] [Related]
2. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches.
Suggitt M; Bibby MC
Clin Cancer Res; 2005 Feb; 11(3):971-81. PubMed ID: 15709162
[TBL] [Abstract][Full Text] [Related]
3. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.
Voskoglou-Nomikos T; Pater JL; Seymour L
Clin Cancer Res; 2003 Sep; 9(11):4227-39. PubMed ID: 14519650
[TBL] [Abstract][Full Text] [Related]
4. The hollow fibre model in cancer drug screening: the NCI experience.
Decker S; Hollingshead M; Bonomi CA; Carter JP; Sausville EA
Eur J Cancer; 2004 Apr; 40(6):821-6. PubMed ID: 15120037
[TBL] [Abstract][Full Text] [Related]
5. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development.
Peterson JK; Houghton PJ
Eur J Cancer; 2004 Apr; 40(6):837-44. PubMed ID: 15120039
[TBL] [Abstract][Full Text] [Related]
6. [Predictability of preclinical evaluation of anticancer drugs by human gastrointestinal cancer--nude mouse panel].
Fujita M; Fujita F; Sakamoto Y; Sugimoto T; Shimozuma K; Taguchi T
Gan To Kagaku Ryoho; 1991 Jul; 18(9):1429-37. PubMed ID: 1854213
[TBL] [Abstract][Full Text] [Related]
7. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
8. Chemoinformatic analysis of NCI preclinical tumor data: evaluating compound efficacy from mouse xenograft data, NCI-60 screening data, and compound descriptors.
Wallqvist A; Huang R; Covell DG
J Chem Inf Model; 2007; 47(4):1414-27. PubMed ID: 17555311
[TBL] [Abstract][Full Text] [Related]
9. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
10. [Preclinical evaluation of anticancer drugs: a model remaining a model!].
Lavelle F
Bull Cancer; 1998 Oct; 85(10):837-42. PubMed ID: 9835860
[TBL] [Abstract][Full Text] [Related]
11. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
12. Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development (review).
Winograd B; Boven E; Lobbezoo MW; Pinedo HM
In Vivo; 1987; 1(1):1-13. PubMed ID: 2979758
[TBL] [Abstract][Full Text] [Related]
13. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages.
Bibby MC
Eur J Cancer; 2004 Apr; 40(6):852-7. PubMed ID: 15120041
[TBL] [Abstract][Full Text] [Related]
14. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.
Man S; Munoz R; Kerbel RS
Cancer Metastasis Rev; 2007 Dec; 26(3-4):737-47. PubMed ID: 17846863
[TBL] [Abstract][Full Text] [Related]
15. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
17. The mighty mouse: genetically engineered mouse models in cancer drug development.
Sharpless NE; Depinho RA
Nat Rev Drug Discov; 2006 Sep; 5(9):741-54. PubMed ID: 16915232
[TBL] [Abstract][Full Text] [Related]
18. New xenograft model for assessing experimental therapy of central nervous system tumors: human glioblastoma in the intrathecal compartment of the nude mouse.
Abernathey CD; Kooistra KL; Wilcox GL; Laws ER
Neurosurgery; 1988 May; 22(5):877-81. PubMed ID: 2837674
[TBL] [Abstract][Full Text] [Related]
19. Strategy for the development of novel anticancer drugs.
Saijo N; Tamura T; Nishio K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
[TBL] [Abstract][Full Text] [Related]
20. Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents.
Kelner MJ; McMorris TC; Estes L; Starr R; Samson K; Varki N; Taetle R
Anticancer Res; 1995; 15(3):867-71. PubMed ID: 7645973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
